Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of ART-123 with FOLFOX and bevacizumab in metastatic colorectal cancer
jRCT2051240258Phase 1Active, not recruiting
- Sponsor
- Asahi Kasei Corporation
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of thrombomodulin alfa in metastatic colorectal adenocarcinoma (mCRC) and peripheral neuropathy (CIPN), sponsored by Asahi Kasei Corporation. Primary endpoints: Safety endpoints and Pharmacokinetic endpoints. Started Mar 2025; status: active, not recruiting.
02
Drugs
thrombomodulin alfa
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on jRCT2051240258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240258.